ATP5PD

Across TCGA pan-cancer cohorts, ATP5PD mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of ATP5PD’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where ATP5PD mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ATP5PD is over-expressed in tumor, although a few such as CCRCC and HNSC show the opposite, repressed pattern.

CCRCC, HNSC, and COAD are the cancer types where ATP5PD tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ATP5PD mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	III,IV	−0.876	<.001	12	view →
HNSC	All	II,III,IV	−0.931	<.001	11	view →
COAD	Male	II,III,IV	−0.369	<.001	10	view →
LSCC	Female	All	+0.248	<.001	7	view →
LUAD	All	All	+0.129	<.001	6	view →
OV	All	All	+0.412	.028	2	view →
PDAC	All	All	−0.205	.035	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

ATP5PD–CCRCC

Open the CCRCC breakdown →